A propensity score-matched cohort study of patients treated for chronic obstructive pulmonary disease (COPD) in routine practice found that the use of generic and brand-name fluticasone–salmeterol was ...
The Towards a Revolution in COPD Health (TORCH) trial evaluated the effect of treatments for chronic obstructive pulmonary disease (COPD) on morbidity and mortality outcomes. The study randomized ...
This product is used to control and prevent symptoms (wheezing and shortness of breath) caused by asthma. It contains 2 medications: fluticasone and salmeterol. Fluticasone belongs to a class of drugs ...
October 27, 2006 (Salt Lake City) -- New findings from the landmark Towards a Revolution in COPD Health (TORCH) study show that high-dose inhaled fluticasone propionate 500 mg/salmeterol 50 mg ( ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results